A process for reducing Nox emissions during fluid catalytic cracking

Details for Australian Patent Application No. 2006240437 (hide)

Owner W.R. Grace & Co.-Conn.

Inventors Ziebarth, Michael S.; Krishnamoorthy, Meenakshi Sundaram; Lussier, Roger J.

Agent Davies Collison Cave

Pub. Number AU-B-2006240437

PCT Pub. Number WO2006/115665

Priority 60/675,150 27.04.05 US

Filing date 24 March 2006

Wipo publication date 2 November 2006

Acceptance publication date 6 October 2011

International Classifications

B01J 29/65 (2006.01) Catalysts comprising molecular sieves

B01J 23/06 (2006.01) Catalysts comprising metals or metal oxides or hydroxides, not provided for in group - of zinc, cadmium or mercury

B01J 23/745 (2006.01) Catalysts comprising metals or metal oxides or hydroxides, not provided for in group - Iron

B01J 29/072 (2006.01) Catalysts comprising molecular sieves

B01J 29/68 (2006.01) Catalysts comprising molecular sieves

B01J 29/80 (2006.01) Catalysts comprising molecular sieves

C10G 11/05 (2006.01) Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils

C10G 11/18 (2006.01) Catalytic cracking, in the absence of hydrogen, of hydrocarbon oils

Event Publications

15 November 2007 PCT application entered the National Phase

  PCT publication WO2006/115665 Priority application(s): WO2006/115665

6 October 2011 Application Accepted

  Published as AU-B-2006240437

2 February 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006240440-Stabilized boehmite-derived catalyst supports, catalysts, methods of making and using

2006240432-Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis